Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Bausch Health Companies Inc. Stock Research

BHC

8.34USD+0.62(+8.03%)Market Closed
Watchlist

Market Summary

USD8.34+0.62
Market Closed
8.03%

BHC Alerts

  • Big jump in Earnings (Y/Y)

BHC Stock Price

BHC RSI Chart

BHC Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-15.11

Price/Sales (Trailing)

0.34

EV/EBITDA

0.84

Price/Free Cashflow

-4.51

BHC Price/Sales (Trailing)

BHC Profitability

EBT Margin

-2.25%

Return on Equity

-86.54%

Return on Assets

-1.4%

Free Cashflow Yield

-22.17%

BHC Fundamentals

BHC Revenue

Revenue (TTM)

8.3B

Revenue Y/Y

10.17%

Revenue Q/Q

11.47%

BHC Earnings

Earnings (TTM)

-186.0M

Earnings Y/Y

117.93%

Earnings Q/Q

112.94%

Price Action

52 Week Range

5.5710.23
(Low)(High)

Last 7 days

-9.9%

Last 30 days

-7.5%

Last 90 days

4.8%

Trailing 12 Months

4.5%

BHC Financial Health

Current Ratio

1.08

BHC Investor Care

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

-0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BHC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-06
Carson Seana
sold
-55,351
8.28
-6,685
evp, general counsel
2023-09-05
Barresi John S
sold (taxes)
-33,249
8.35
-3,982
svp, controller & cao
2023-09-05
Vadaketh Tom George
sold (taxes)
-366,966
8.35
-43,948
evp, chief financial officer
2023-09-05
Carson Seana
sold (taxes)
-428,664
8.35
-51,337
evp, general counsel
2023-09-01
APPIO THOMAS
sold (taxes)
-119,379
8.46
-14,111
chief executive officer
2023-06-30
Paulson John
acquired
62,496
8.00
7,812
-
2023-06-30
ICAHN BRETT
acquired
33,120
8.00
4,140
-
2023-06-30
ROBERTSON RUSSEL C
acquired
31,248
8.00
3,906
-
2023-06-30
WECHSLER AMY B
acquired
6,872
8.00
859
-
2023-06-20
Barresi John S
sold (taxes)
-14,274
7.4
-1,929
svp, controller & cao

1–10 of 50

Which funds bought or sold BHC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-07
ACADEMY CAPITAL MANAGEMENT INC/TX
reduced
-57.97
-560,872
398,128
0.08%
2023-08-24
Alberta Investment Management Corp
reduced
-23.93
-793,779
2,421,600
0.02%
2023-08-23
WOLVERINE TRADING, LLC
added
55.79
149,484
405,484
-%
2023-08-23
Stonebridge Capital Advisors LLC
reduced
-13.89
-4,360
24,800
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-10.37
-29,303
255,554
-%
2023-08-16
GTS SECURITIES LLC
new
-
930,872
930,872
0.03%
2023-08-15
Rokos Capital Management LLP
new
-
14,078,100
14,078,100
0.14%
2023-08-15
IHT Wealth Management, LLC
reduced
-10.06
-10,316
82,000
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
new
-
49,000
49,000
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
18.9
2,085,930
14,049,700
-%

1–10 of 37

Latest Funds Activity

Are funds buying BHC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BHC
No. of Funds

Schedule 13G FIlings of Bausch Health Companies

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
nomura holdings inc
3.6%
13,030,352
SC 13G/A
Feb 13, 2023
goldentree asset management lp
5.4%
19,421,054
SC 13G
May 13, 2022
va partners i, llc
4.0%
14,430,901
SC 13D/A
Feb 14, 2022
nomura holdings inc
5.4%
19,515,079
SC 13G
Dec 13, 2021
glenview capital management, llc
4.75%
17,078,657
SC 13D/A
Jun 21, 2021
va partners i, llc
5.0%
17,941,603
SC 13D/A
Apr 23, 2021
meruelo alex
5.51%
19,604,777
SC 13G
Mar 16, 2021
icahn carl c
3.98%
14,169,189
SC 13D/A
Mar 11, 2021
icahn carl c
3.98%
14,169,189
SC 13D/A
Feb 24, 2021
icahn carl c
-
0
SC 13D/A

Recent SEC filings of Bausch Health Companies

View All Filings
Date Filed Form Type Document
Sep 18, 2023
8-K
Current Report
Sep 14, 2023
8-K
Current Report
Sep 11, 2023
8-K
Current Report
Sep 06, 2023
144
Notice of Insider Sale Intent
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
8-K
Current Report
Sep 05, 2023
4
Insider Trading
Aug 03, 2023
8-K
Current Report

Peers (Alternatives to Bausch Health Companies)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
517.3B
29.5B
5.22% 88.98%
79.61
17.53
1.53% 14.16%
421.5B
97.8B
-5.97% -1.12%
32.29
4.31
2.29% -28.92%
272.8B
58.3B
-1.68% 25.60%
17.88
4.63
2.00% -81.24%
191.9B
77.9B
-7.28% -24.56%
8.94
2.46
-23.04% -26.74%
150.1B
45.2B
-5.53% -15.83%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.68% 536.50%
-74
4.1K
-86.94% 71.24%
4.5B
4.6B
-12.08% -16.86%
-67.03
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-8.17% -19.68%
35.6
2.43
0.62% -24.59%
842.2M
109.5M
18.82% -27.78%
-5.87
7.69
-2.66% -32.13%
814.0M
244.3M
-8.50% 0.08%
4.13
3.33
-39.50% -4.99%
567.0M
453.3M
123.19% -68.11%
-0.46
1.25
-16.04% 55.90%
523.7M
31.2M
3.50% -46.76%
-4.97
16.8
407.54% -26.47%
269.4M
54.6M
-19.05% -43.62%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Bausch Health Companies News

Nasdaq
CANADA STOCKS-TSX ends lower as Fed sticks to inflation fight.
Nasdaq,
2 hours ago
The Motley Fool
The Motley Fool
Digital Journal

Returns for BHC

Cumulative Returns on BHC

-22.9%


10-Year Cumulative Returns

-16.1%


7-Year Cumulative Returns

-20.9%


5-Year Cumulative Returns

-23.4%


3-Year Cumulative Returns

Risks for BHC

What is the probability of a big loss on BHC?

97.3%


Probability that Bausch Health Companies stock will be more than 20% underwater in next one year

72.7%


Probability that Bausch Health Companies stock will be more than 30% underwater in next one year.

46.9%


Probability that Bausch Health Companies stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BHC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bausch Health Companies was unfortunately bought at previous high price.

Drawdowns

Financials for Bausch Health Companies

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.5%8,350,000,0008,150,000,0008,124,000,0008,127,000,0008,192,000,0008,325,000,0008,434,000,0008,451,000,0008,478,000,0008,042,000,0008,027,000,0008,038,000,0008,109,000,0008,597,000,0008,601,000,0008,498,000,0008,425,000,0008,401,000,0008,380,000,0008,422,000,0008,505,000,000
  S&GA Expenses1.3%2,763,000,0002,728,000,0002,625,000,0002,639,000,0002,631,000,0002,640,000,0002,624,000,0002,580,000,0002,499,000,0002,340,000,0002,367,000,0002,399,000,0002,475,000,0002,600,000,0002,554,000,0002,512,000,0002,478,000,0002,469,000,0002,473,000,0002,486,000,0002,495,000,000
EBITDA-100.0%-2,587,000,0002,729,000,0003,146,000,0002,936,000,0002,406,000,0001,954,000,0001,640,000,0001,576,000,0001,906,000,0002,425,000,0001,425,000,0001,400,000,0001,733,000,0001,850,000,000------
EBITDA Margin-100.0%-0.320.340.390.360.290.230.190.190.240.300.180.170.200.22------
Interest Expenses-6.5%1,318,000,0001,409,000,0001,464,000,0001,500,000,0001,466,000,0001,420,000,0001,426,000,0001,462,000,0001,485,000,0001,506,000,0001,534,000,0001,546,000,0001,578,000,0001,602,000,0001,612,000,0001,628,000,0001,630,000,0001,624,000,0001,685,000,000--
Earnings Before Taxes113.7%25,000,000-183,000,000-129,000,000249,000,00026,000,000-515,000,000-1,024,000,000-1,439,000,000-1,580,000,000-1,347,000,000-934,000,000-2,010,000,000-2,151,000,000-1,893,000,000-1,837,000,000-793,000,000-1,027,000,000-1,582,000,000-4,154,000,000-4,532,000,000-4,632,000,000
EBT Margin100.0%--0.02-0.020.030.00-0.06-0.12-0.17-0.19-0.17-0.12-0.25-0.27-0.22-0.21------
Net Income47.9%-186,000,000-357,000,000-225,000,000254,000,00043,000,000-407,000,000-948,000,000-1,170,000,000-1,287,000,000-1,018,000,000-560,000,000-1,923,000,000-2,043,000,000-1,888,000,000-1,788,000,000-616,000,000-917,000,000-1,619,000,000-4,148,000,000-3,291,000,000-1,640,000,000
Net Income Margin100.0%--0.04-0.030.030.01-0.05-0.11-0.14-0.15-0.13-0.07-0.24-0.25-0.22-0.21------
Free Cashflow100.0%--730,000,000-946,000,000-1,409,000,000409,000,000671,000,0001,157,000,0001,525,000,0001,199,000,000997,000,000809,000,000651,000,000908,000,0001,054,000,0001,231,000,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.2%25,50325,44525,68626,29828,17129,09029,20229,25230,04230,19731,19931,56231,39632,63033,86331,66732,35432,55132,49233,77734,448
  Current Assets5.3%4,4614,2374,2474,0105,4175,8365,6075,3245,4505,3925,3425,6715,2785,5046,9694,3054,4674,2754,2114,7424,639
    Cash Equivalents11.8%5795185644866591,2492,1196906426796059778969123,244825878782721973838
  Inventory1.5%1,2401,2221,0901,0561,0731,0459931,0581,0861,0761,0941,2241,2261,1241,1071,1001,0601,012934971993
  Net PPE0.2%1,5991,5961,6001,5071,5451,5791,5981,5841,5901,5561,5671,5501,4961,4501,4661,3901,3721,3411,3531,3411,355
  Goodwill0.4%11,62811,57911,54712,04412,26612,42712,45712,47712,52712,48513,04413,16013,08413,03413,12613,05213,16013,12113,14213,29013,283
Liabilities-0.3%25,23225,30025,42625,86527,91829,23129,23629,38730,65330,32130,59430,90730,85031,07532,72729,10729,66629,77229,67730,54030,890
  Current Liabilities1.1%3,9673,9233,9413,8314,9974,7745,1985,4375,5174,8984,9134,7324,7184,8866,2483,7353,7053,9413,8364,1624,074
    LT Debt, Current-0.4%444446432411150-------1.004.001,23410056.00257228298230
    LT Debt, Non Current-0.5%20,10820,20720,33420,80421,66423,16822,65422,35823,43923,73823,92524,34324,35724,42424,66123,46624,02323,92424,07724,43324,858
Shareholder's Equity86.9%271145260-253-141-34.00---6056555467901,1362,5602,6882,7792,8153,2373,558
  Retained Earnings0.3%-9,361-9,387-9,186-8,776-9,175-9,030-8,961-9,030-9,218-8,623-8,013-7,860-7,931-7,605-7,452-5,936-5,887-5,716-5,664-5,320-4,970
  Additional Paid-In Capital9.9%188171159129104415462437413393454435411396429406384374413409391
Shares Outstanding0.1%364364362362362361359360359357355356355353353352352351351352351
Minority Interest-1.2%93494595295894675.0072.0069.0076.0073.0070.0068.0072.0071.0073.0078.0087.0086.0082.0084.0091.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations16.2%-428-511-728-1,1796489201,4261,7961,4881,2931,1119511,2101,3491,5011,5861,5931,4761,5011,7601,728
  Share Based Compensation5.2%14213512612412412912811911310910510610510510299.0095.0090.0087.0082.0079.00
Cashflow From Investing8.6%-297-325-303-247394409409405-253-277-261-262-265-256-419-396-318-351-196-44.00820
Cashflow From Financing47.0%-574-1,084-47477.00-1,044-802-1,513-2,291-1,251-1,016-2,29446410772.001,443-1,314-1,226-1,215-1,353-2,693-3,737

BHC Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues    
Revenues$ 2,167$ 1,967$ 4,111$ 3,885
Expenses    
Selling, general and administrative7116761,4361,298
Research and development156127299254
Amortization of intangible assets269302542612
Goodwill impairments083083
Asset impairments3765014
Restructuring, integration, separation and IPO costs16352648
Other (income) expense, net(83)0(60)2
Total expenses1,7551,8063,5243,439
Operating income412161587446
Interest income73135
Interest expense(319)(410)(626)(772)
Gain on extinguishment of debt01130113
Foreign exchange and other(21)4(31)(3)
Income (loss) before income taxes79(129)(57)(211)
(Provision for) benefit from income taxes(52)(10)(125)6
Net income (loss)27(139)(182)(205)
Net (income) loss attributable to noncontrolling interest(1)(6)7(9)
Net income (loss) attributable to Bausch Health Companies Inc.$ 26$ (145)$ (175)$ (214)
Earnings (loss) per share attributable to Bausch Health Companies Inc.    
Basic (in usd per share)$ 0.07$ (0.40)$ (0.48)$ (0.59)
Diluted (in usd per share)$ 0.07$ (0.40)$ (0.48)$ (0.59)
Weighted-average common shares    
Basic (in shares)364.8362.2364.1361.5
Diluted (in shares)367.1362.2364.1361.5
Product sales    
Revenues    
Revenues$ 2,146$ 1,944$ 4,068$ 3,835
Expenses    
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues6405681,2121,104
Other revenues    
Revenues    
Revenues21234350
Expenses    
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues$ 9$ 9$ 19$ 24

BHC Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 579$ 564
Restricted cash927
Trade receivables, net1,7431,790
Inventories, net1,2401,090
Prepaid expenses and other current assets890776
Total current assets4,4614,247
Property, plant and equipment, net1,5991,600
Intangible assets, net5,2995,800
Goodwill11,62811,547
Deferred tax assets, net2,1912,166
Other non-current assets325326
Total assets25,50325,686
Current liabilities:  
Accounts payable515521
Accrued and other current liabilities3,0082,988
Current portion of long-term debt444432
Total current liabilities3,9673,941
Acquisition-related contingent consideration197208
Non-current portion of long-term debt20,10820,334
Deferred tax liabilities, net215202
Other non-current liabilities745741
Total liabilities25,23225,426
Commitments and contingencies (Note 17)
Equity  
Common shares, no par value, unlimited shares authorized, 364,063,514 and 361,898,846 issued and outstanding at June 30, 2023 and December 31, 2022, respectively10,41210,391
Additional paid-in capital188159
Accumulated deficit(9,361)(9,186)
Accumulated other comprehensive loss(1,902)(2,056)
Total Bausch Health Companies Inc. shareholders’ deficit(663)(692)
Noncontrolling interest934952
Total equity271260
Total liabilities and equity$ 25,503$ 25,686
Robert N. Power
19100
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.